Company news
Biomx Inc. (AMEX:PHGE) news
Biomx Inc. news releases on 6ix. Latest, Aug 5, 2026: BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone…
Press releases & updates
BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems
August 5, 2026
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
June 12, 2026
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
May 27, 2026
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
May 6, 2026
Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems
April 16, 2026
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
April 13, 2026
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
April 10, 2026
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
March 31, 2026
BiomX Adds Former Mossad Deputy to Advisory Board
March 30, 2026
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
March 27, 2026
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
March 26, 2026
BiomX CEO Issues Letter to Stockholders
March 19, 2026
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
March 9, 2026
BiomX Issues Statement Regarding Recent Common Stock Trading Activity
January 27, 2026
BiomX Announces $3.0 Million Private Placement
December 29, 2025
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
December 8, 2025
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
November 25, 2025
BiomX Inc. Announces 1-for-19 Reverse Stock Split
November 14, 2025
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
November 12, 2025
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
November 5, 2025
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
November 4, 2025
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
October 17, 2025
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
August 19, 2025
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
August 13, 2025
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
August 6, 2025
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
July 14, 2025
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
July 8, 2025
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
May 19, 2025
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
May 15, 2025
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
May 8, 2025